Collaboration investigates enhanced manufacturing of AAV and lentiviral vectors to improve quality and productivity for gene therapy and vaccine developers.
Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain
Charles River Laboratories and Pfizer have entered into a marketing and distribution agreement to provide certain Pfizer-developed genetically modified research models to the biomedical research community.
Charles River Laboratories International, Inc. released its business outlook, highlighting its portfolio and its plan to focus on four key initiatives in an effort to drive shareholder value.
Charles River Laboratories has entered into an exclusive, long-term marketing and distribution agreement with Transposagen Biopharmaceuticals, Inc., a KY-based provider of genetically modified rat models.
Charles River Laboratories' Shanghai facility has received a Certificate of Good Laboratory Practice (GLP) compliance from the Organization for Economic Cooperation and Development (OECD).
Chiltern International and Charles River Laboratories have entered into a collaboration under which Chiltern Early Phase will partner with Charles River to conduct and support radiolabelled studies.
Charles River Laboratories has decided to suspend operations at its Preclinical Services (PCS) facility in Shrewsbury, MA by mid-2010, once ongoing studies are completed.
Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand.
PPD, Inc. has entered into a definitive agreement to sell its wholly-owned subsidiary Piedmont Research Center, LLC to Charles River Laboratories for $46.0 million in cash.